AbClon Inc.

A174900

KR7174900001

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
15,940 ^KRW	-2.33%		-4.67%	+7.56%

2023	AbClon Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
2023	AbClon Presents Non-Clon and Phase 1 Interim Results of its AT101 Novel CAR-T Therapy at the Annual 2023 AACR Conference	CI

AbClon Inc. announced that it has received KRW 13.999902624 billion in funding

November 27, 2019

On November 28, 2019, AbClon Inc. (KOSDAQ:A174900) closed the transaction.

Latest news about AbClon Inc.

AbClon Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
AbClon Presents Non-Clon and Phase 1 Interim Results of its AT101 Novel CAR-T Therapy at the Annual 2023 AACR Conference	23-04-17	CI
AbClon Inc. announced that it has received KRW 11.999976975 billion in funding from Quad Investment Management Corp.	22-09-27	CI
AbClon Inc. announced that it has received KRW 10 billion in funding from Quad Investment Management Corp.	22-07-27	CI
AbClon Inc. announced that it expects to receive KRW 11.999976975 billion in funding from Quad Investment Management Corp.	22-07-25	CI
AbClon Inc. announced that it expects to receive KRW 10 billion in funding from Quad Investment Management Corp.	22-07-25	CI
AbClon Inc. announced that it has received KRW 13.999902624 billion in funding	19-11-27	CI
AbClon Inc. announced that it expects to receive KRW 13.999902624 billion in funding	19-11-13	CI
AbClon Inc.(KOSDAQ:A174900) added to S&P Global BMI Index	17-12-18	CI
AbClon Inc. has completed an IPO in the amount of KRW 6.80741 billion.	17-09-17	CI
AbClon Inc. has filed an IPO.	17-05-18	CI
AbClon Inc. has withdrawn its IPO.	17-05-17	CI
AbClon Inc. has filed an IPO.	15-10-08	CI

AbClon Inc. is a Korea-based company principally engaged in the development, manufacture and distribution of antibody drug. The Company developed a bio synergy antibody, a therapeutic antibody for a new mechanism that is different from conventional therapeutic agents, and is based on the YPLUS and AffiMab platforms. The company's products include AC101, AC103, AC104, AC106, AC203, AM201, AM101, AM102 and AM103. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-05-22 - NH Investment & Securities Forum

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
ABCLON INC.	+7.56%	193M
CSL LIMITED	-2.32%	90.45B
SAMSUNG BIOLOGICS CO.,LTD.	+3.68%	41.45B
BIOGEN INC.	-10.90%	33.57B
UCB	+58.05%	25.73B
BIOMARIN PHARMACEUTICAL INC.	-19.56%	14.73B
INCYTE CORPORATION	-9.06%	12.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.34%	11.7B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.53%	11.44B
SWEDISH ORPHAN BIOVITRUM AB	+3.75%	8.79B

Biopharmaceuticals

AbClon Inc.

Equities

A174900

KR7174900001

Pharmaceuticals

AbClon Inc. announced that it has received KRW 13.999902624 billion in funding

Latest news about AbClon Inc.

Chart AbClon Inc.

Company Profile

Income Statement Evolution

Sector Biopharmaceuticals